Aim for lower LDL-C target?

The findings help answer the long-standing debate questioning the clinical benefit of further reducing LDL-C, said Professor Phil Aylward, an Australian investigator on the IMPROVE-IT trial and director of cardiac services at the Southern Adelaide Local Health Network.

“The study shows it doesn’t matter how you lower LDL — it doesn’t have to be a statin — if you lower LDL further in high-risk patients, you reduce CV events, he said.”

It could mean that